Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting
October 02 2019 - 7:00AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
that four abstracts highlighting its TIL therapy will be presented
at the upcoming Society for Immunotherapy of Cancer (SITC) 34th
Annual Meeting from November 6-10, 2019 in National Harbor,
Maryland. One of the abstracts is a late-breaking submission and
presentation details will be made available to the public on
November 1, 2019. Details on the three posters that will be
presented as part of the regular submissions are below.
Title: Expanding Iovance’s tumor infiltrating
lymphocytes (TIL) from core biopsies for adoptive T cell therapy
using a 22-day manufacturing processAuthor:
Abelson et al.Poster #: P145Presentation
date/time: November 8, 2019, 7:00 am - 8:00 pm
Title: Silencing PD-1 using self-delivering
RNAi PH-762 to improve Iovance TIL effector function using Gen 2
manufacturing methodAuthor: Azoulay-Alfaguter et
al.Poster #:
P149Presentation date/time: November 8, 2019, 7:00
am - 8:00 pm
Title: Iovance Gen2 TIL manufacturing process
produces drug products that exhibit favorable quality attributes
for adoptive cell transfer across 5 solid tumor
indicationsAuthor: Wardell et al.Poster
#: P226Presentation date/time: November
9, 2019, 7:00 am - 8:30 pm
The SITC abstract titles are listed on the conference website
under Abstracts at
https://sitc.sitcancer.org/2019/abstracts/titles.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to improve patient care by making T
cell-based immunotherapies broadly accessible for the treatment of
patients with solid tumors and blood cancers. Tumor infiltrating
lymphocyte (TIL) therapy uses a patient’s own immune cells to
attack cancer. TIL cells are extracted from a patient’s own tumor
tissue, expanded through a proprietary process, and infused back
into the patient. After infusion, TIL reach tumor tissue, where
they attack tumor cells. The company is currently conducting
pivotal studies in patients with metastatic melanoma and advanced
cervical cancer. In addition, the company’s TIL therapies are being
investigated for the treatment of patients with locally advanced,
recurrent or metastatic cancers including head and neck and
non-small cell lung cancer. Clinical studies of T cell therapy for
blood cancers called peripheral blood lymphocyte (PBL) therapy are
being planned. For more information, please visit
www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. The forward-looking
statements include, but are not limited to, risks and uncertainties
relating to the success, timing, projected enrollment,
manufacturing and production capabilities, and cost of our ongoing
clinical trials and anticipated clinical trials for our current
product candidates (including both Company-sponsored and
collaborator-sponsored trials in both the U.S. and Europe), such as
statements regarding the timing of initiation and completion of
these trials; the timing of and our ability to successfully submit,
obtain and maintain FDA or other regulatory authority approval of,
or other action with respect to, our product candidates, including
those product candidates that have been granted breakthrough
therapy designation (“BTD”) or regenerative medicine advanced
therapy designation (“RMAT”) by the FDA and new product candidates
in both solid tumor and blood cancers; the strength of the
Company’s product pipeline; the successful implementation of the
Company’s research and development programs and collaborations; the
Company’s ability to obtain tax incentives and credits; the
guidance provided for the Company’s future cash, cash equivalent,
and short term investment positions; the success of the Company’s
manufacturing, license or development agreements; the acceptance by
the market of the Company’s product candidates, if approved; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in the
Company’s business, including, without limitation: the preliminary
clinical results, which may include efficacy and safety results,
from ongoing Phase 2 studies may not be reflected in the final
analyses of these trials; the rate of enrollment may impact the
Company’s clinical trial timelines; enrollment may need to be
adjusted for the Company’s trials and cohorts within those trials
based on FDA and other regulatory agency input; the new version of
the protocol which further defines the patient population to
include more advanced patients in the Company’s cervical cancer
trial may have an adverse effect on the results reported to date;
the data within these trials may not be supportive of product
approval; the Company’s ability to address FDA or other regulatory
authority requirements relating to its clinical programs and
registrational plans, such requirements including, but not limited
to, clinical, safety, manufacturing and control requirements; the
Company’s interpretation of communications with the FDA; risks
related to the Company’s ability to maintain and benefit from
accelerated FDA review designations, including BTD and RMAT, which
may not result in a faster development process or review of the
Company’s product candidates (and which may later be rescinded by
the FDA), and does not assure approval of such product candidates
by the FDA or the ability of the Company to obtain FDA approval in
time to benefit from commercial opportunities; and the ability of
the Company to manufacture its therapies using third party
manufacturers. A further list and description of the Company’s
risks, uncertainties and other factors can be found in the
Company’s most recent Annual Report on Form 10-K and the Company’s
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov or
www.iovance.com. The forward-looking statements are made only as of
the date of this press release and the Company undertakes no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024